BridgeBio Pharma, Inc. (BBIO)
Upgrades & Downgrades
Latest BBIO news
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
22 June 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan d...
BridgeBio Pharma: Yet To Be Proven Business Model
9 June 2022
BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked.
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal...
9 June 2022
- BridgeBio will host an investor call on June 13, 2022, at 4:30 pm ET to discuss the Phase 2b study results and the planned pivotal Phase 3 study design
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
13 May 2022
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
5 May 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and ex...
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in...
28 March 2022
PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and...
BridgeBio: Potential Based On Diverse Pipeline Targeting KRAS Mutations And Rare Diseases
22 March 2022
First patient dosed in phase 1/2 ADventure study which is using BBP-631 for the treatment of patients with congenital adrenal hyperplasia; results from the study expected 2nd half of 2022.
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
14 March 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and...
12 biotech stocks to consider buying now as prospects for the sector brighten this year
6 February 2022
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double